News & Updates

TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
21 Oct 2024 byStephen Padilla

The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.

TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
21 Oct 2024
1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cance
1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer
21 Oct 2024
Prior local therapy enhances apalutamide’s effect on metastasis-free survival
Prior local therapy enhances apalutamide’s effect on metastasis-free survival
21 Oct 2024